Summary:
- The article explores emerging research into the potential repurposing of ivermectin, an antiparasitic drug, as an adjunct therapy in oncology.
- It highlights preliminary laboratory and in vitro studies suggesting ivermectin may inhibit tumor growth and induce apoptosis in certain cancer cell lines.
- The piece emphasizes the critical need for rigorous, large-scale clinical trials to validate these findings, cautioning against self-medication or the premature labeling of the drug as a "cure."